Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | GGH | Q92820 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3926158 | 1.00 | LMNA (0.57) | LMNABLMFOLH1NAALAD2RIMKLA | |
| SCHEMBL8647821 | 0.88 | BLM (0.48) | LMNABLMFOLH1CCKBREPHX2 | |
| SCHEMBL10935612 | 0.85 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGHEPHX2 | |
| SCHEMBL10935609 | 0.85 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGHEPHX2 | |
| SCHEMBL29501687 | 0.80 | EPHX2 (0.53) | LMNAFOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL1352750 | 0.77 | LMNA (0.49) | LMNABLMEPHX2 | |
| Hydrochloric Acid SCHEMBL28923980 | 0.77 | LMNA (0.40) | LMNABLMEPHX2 | |
| SCHEMBL1352747 | 0.77 | LMNA (0.49) | LMNABLMEPHX2 | |
| SCHEMBL1352745 | 0.77 | LMNA (0.49) | LMNABLMEPHX2 | |
| SCHEMBL3913759 | 0.75 | LMNA (0.47) | LMNABLMEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940376-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2008-07-09 | — | — | EP | claimed |
| WO-2007039869-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2007-04-12 | — | — | WO | claimed |
| EP-1940376-B1 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM SPA (IT) | 2009-03-18 | — | — | EP | disclosed |
| EP-1940376-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007039869-A3 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM SPA (IT) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007039869-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2007-04-12 | — | — | WO | disclosed |